zamtocabtagene autoleucel
Cell therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2025 (NCT06708845)
Timeline
Indications
Mechanism of action
- B-lymphocyte antigen CD20Immunity, passive
MS4A1 immunity, passive
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06508931 | Phase 2 | Apr 1, 2025 | Miltenyi Biotec, Inc. |
| NCT06708845 | Phase 1 | Jan 31, 2025 | Miltenyi Biotec, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Miltenyi Biotec, Inc. | For profit | 2 | 2 | 2 | 2025 |
1 organizations
Page 1 / 1